Intravenous immunoglobulin promotes antitumor responses by modulating macrophage polarization

Journal of Immunology

Volumn 193, Issue 10, 2014, Pages 5181-5189

  Domínguez Soto, Angeles ^a   De Las Casas Engel, Mateo ^a   Bragado, Rafael ^b   Medina Echeverz, José ^c   Aragoneses Fenoll, Laura ^a   Martín Gayo, Enrique ^d   Van Rooijen, Nico ^e   Berraondo, Pedro ^c   Toribio, María L ^d   Moro, María A ^e   Cuartero, Isabel ^f   Castrillo, Antonio ^d   Sancho, David ^g   Sánchez Torres, Carmen ^h   Bruhns, Pierre ^i,j   Sánchez Ramón, Silvia ^k   Corbí, Angel L ^a  

^a CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^b INSTITUTO DE INVESTIGACIÓN SANITARIA DEL HOSPITAL CLÍNICO SAN CARLOS IDISSC   (Spain)

^c UNIVERSITY OF NAVARRA   (Spain)

^d CSIC   (Spain)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^g CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^h DEPARTAMENTO DE FÍSICA   (Mexico)

ⁱ INSTITUT PASTEUR   (France)

^j INSERM   (France)

^k HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; FC RECEPTOR; FC RECEPTOR GAMMA; FC RECEPTOR IV; IMMUNOGLOBULIN G; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CYTOKINE; FCGR3 PROTEIN, MOUSE; FCGR4 PROTEIN, MOUSE; IMMUNOGLOBULIN; IMMUNOGLOBULIN E RECEPTOR; IMMUNOLOGIC FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; BRAIN ISCHEMIA; CANCER INHIBITION; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MACROPHAGE FUNCTION; MACROPHAGE POLARIZATION; MELANOMA; METASTASIS INHIBITION; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; REPOLARIZATION; SEPTIC SHOCK; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; ANIMAL; CANCER TRANSPLANTATION; CELL CULTURE; CELL DIFFERENTIATION; CLASSIFICATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LUNG; LUNG NEOPLASMS; MACROPHAGE; MELANOMA, EXPERIMENTAL; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; CELLS, CULTURED; CYTOKINES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; LUNG; LUNG NEOPLASMS; MACROPHAGES; MELANOMA, EXPERIMENTAL; MICE; NEOPLASM TRANSPLANTATION; RECEPTORS, IGE; RECEPTORS, IGG; SIGNAL TRANSDUCTION; TUMOR BURDEN;

EID: 84910141707     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1303375     Document Type: Article

References (49)

1. Mosser, D. M., and J. P. Edwards. 2008. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8: 958-969
2. Mantovani, A., A. Sica, and M. Locati. 2005. Macrophage polarization comes of age. Immunity 23: 344-346
3. Gordon, S., and F. O. Martinez. 2010. Alternative activation of macrophages: mechanism and functions. Immunity 32: 593-604
4. Mantovani, A., S. Sozzani, M. Locati, P. Allavena, and A. Sica. 2002. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23: 549-555
5. Biswas, S. K., and A. Mantovani. 2010. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 11: 889-896
6. Duffield, J. S., S. J. Forbes, C. M. Constandinou, S. Clay, M. Partolina, S. Vuthoori, S. Wu, R. Lang, and J. P. Iredale. 2005. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J. Clin. Invest. 115: 56-65
7. Olefsky, J. M., and C. K. Glass. 2010. Macrophages, inflammation, and insulin resistance. Annu. Rev. Physiol. 72: 219-246
8. Odegaard, J. I., R. R. Ricardo-Gonzalez, M. H. Goforth, C. R. Morel, V. Subramanian, L. Mukundan, A. Red Eagle, D. Vats, F. Brombacher, A.W. Ferrante, and A. Chawla. 2007. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 447: 1116-1120
9. Hamilton, J. A. 2008. Colony-stimulating factors in inflammation and autoimmunity. Nat. Rev. Immunol. 8: 533-544
10. Lin, E. Y., A. V. Nguyen, R. G. Russell, and J. W. Pollard. 2001. Colonystimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med. 193: 727-740
11. Bingle, L., N. J. Brown, and C. E. Lewis. 2002. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J. Pathol. 196: 254-265
12. Allavena, P., A. Sica, C. Garlanda, and A. Mantovani. 2008. The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol. Rev. 222: 155-161
13. Sica, A., A. Saccani, B. Bottazzi, N. Polentarutti, A. Vecchi, J. van Damme, and A. Mantovani. 2000. Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages. J. Immunol. 164: 762-767
14. Nimmerjahn, F., and J. V. Ravetch. 2008. Anti-inflammatory actions of intravenous immunoglobulin. Annu. Rev. Immunol. 26: 513-533
15. Nimmerjahn, F., and J. V. Ravetch. 2007. Fc-receptors as regulators of immunity. Adv. Immunol. 96: 179-204
16. Clynes, R. 2007. IVIG therapy: interfering with interferon-gamma. Immunity 26: 4-6
17. Gelfand, E. W. 2012. Intravenous immune globulin in autoimmune and inflammatory diseases. N. Engl. J. Med. 367: 2015-2025
18. Park-Min, K. H., N. V. Serbina, W. Yang, X. Ma, G. Krystal, B. G. Neel, S. L. Nutt, X. Hu, and L. B. Ivashkiv. 2007. FcgammaRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin. Immunity 26: 67-78
19. Schwab, I., and F. Nimmerjahn. 2013. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat. Rev. Immunol. 13: 176-189
20. Negi, V. S., S. Elluru, S. Sibéril, S. Graff-Dubois, L. Mouthon, M. D. Kazatchkine, S. Lacroix-Desmazes, J. Bayry, and S. V. Kaveri. 2007. Intravenous immunoglobulin: An update on the clinical use and mechanisms of action. J. Clin. Immunol. 27: 233-245
21. Domínguez-Soto, A., E. Sierra-Filardi, A. Puig-Kröger, B. Pérez-Maceda, F. Gómez-Aguado, M. T. Corcuera, P. Sánchez-Mateos, and A. L. Corbí. 2011. Dendritic cell-specific ICAM-3-grabbing nonintegrin expression on M2-polarized and tumor-associated macrophages is macrophage-CSF dependent and enhanced by tumor-derived IL-6 and IL-10. J. Immunol. 186: 2192-2200
22. Puig-Krö ger, A., E. Sierra-Filardi, A. Domínguez-Soto, R. Samaniego, M. T. Corcuera, F. Gómez-Aguado, M. Ratnam, P. Sánchez-Mateos, and A. L. Corbí. 2009. Folate receptor beta is expressed by tumor-associated macrophages and constitutes a marker for M2 anti-inflammatory/regulatory macrophages. Cancer Res. 69: 9395-9403
23. Martín-Gayo, E., E. Sierra-Filardi, A. L. Corbí, and M. L. Toribio. 2010. Plasmacytoid dendritic cells resident in human thymus drive natural Treg cell development. Blood 115: 5366-5375
24. Fleetwood, A. J., T. Lawrence, J. A. Hamilton, and A. D. Cook. 2007. Granulocyte-macrophage colony-stimulating factor (CSF) and macrophage CSFdependent macrophage phenotypes display differences in cytokine profiles and transcription factor activities: implications for CSF blockade in inflammation. J. Immunol. 178: 5245-5252
25. Fleetwood, A. J., H. Dinh, A. D. Cook, P. J. Hertzog, and J. A. Hamilton. 2009. GM-CSF-and M-CSF-dependent macrophage phenotypes display differential dependence on type I interferon signaling. J. Leukoc. Biol. 86: 411-421
26. Sierra-Filardi, E., A. Puig-Kröger, F. J. Blanco, C. Nieto, R. Bragado, M. I. Palomero, C. Bernabéu, M. A. Vega, and A. L. Corbí. 2011. Activin A skews macrophage polarization by promoting a proinflammatory phenotype and inhibiting the acquisition of anti-inflammatory macrophage markers. Blood 117: 5092-5101
27. de las Casas-Engel, M., A. Domínguez-Soto, E. Sierra-Filardi, R. Bragado, C. Nieto, A. Puig-Kroger, R. Samaniego, M. Loza, M. T. Corcuera, F. Gómez-Aguado, et al. 2013. Serotonin skews human macrophage polarization through HTR2B and HTR7. J. Immunol. 190: 2301-2310
28. Chen, S. T., C. Y. Hsu, E. L. Hogan, H. Maricq, and J. D. Balentine. 1986. A model of focal ischemic stroke in the rat: reproducible extensive cortical infarction. Stroke 17: 738-743
29. Liu, T. H., J. S. Beckman, B. A. Freeman, E. L. Hogan, and C. Y. Hsu. 1989. Polyethylene glycol-conjugated superoxide dismutase and catalase reduce ischemic brain injury. Am. J. Physiol. 256: H589-H593
30. Nimmerjahn, F., and J. V. Ravetch. 2007. The antiinflammatory activity of IgG: the intravenous IgG paradox. J. Exp. Med. 204: 11-15
31. Smith, K. G., and M. R. Clatworthy. 2010. FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat. Rev. Immunol. 10: 328-343
32. Humphrey, M. B., L. L. Lanier, and M. C. Nakamura. 2005. Role of ITAMcontaining adapter proteins and their receptors in the immune system and bone. Immunol. Rev. 208: 50-65
33. Colonna, M. 2007. All roads lead to CARD9. Nat. Immunol. 8: 554-555
34. Mallavia, B., A. Oguiza, O. Lopez-Franco, C. Recio, G. Ortiz-Muñoz, I. Lazaro, V. Lopez-Parra, J. Egido, and C. Gomez-Guerrero. 2013. Gene deficiency in activating Fcg receptors influences the macrophage phenotypic balance and reduces atherosclerosis in mice. PLoS One 8: e66754
35. Iadecola, C., and J. Anrather. 2011. The immunology of stroke: from mechanisms to translation. Nat. Med. 17: 796-808
36. Gabrilovich, D. I., S. Ostrand-Rosenberg, and V. Bronte. 2012. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12: 253-268
37. Sica, A., P. Larghi, A. Mancino, L. Rubino, C. Porta, M. G. Totaro, M. Rimoldi, S. K. Biswas, P. Allavena, and A. Mantovani. 2008. Macrophage polarization in tumour progression. Semin. Cancer Biol. 18: 349-355
38. Bayry, J., N. Misra, V. Latry, F. Prost, S. Delignat, S. Lacroix-Desmazes, M. D. Kazatchkine, and S. V. Kaveri. 2003. Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases. Transfus. Clin. Biol. 10: 165-169
39. Anthony, R. M., and J. V. Ravetch. 2010. A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. J. Clin. Immunol. 30(Suppl. 1): S9-S14
40. Hogarth, P. M., and G. A. Pietersz. 2012. Fc receptor-Targeted therapies for the treatment of inflammation, cancer and beyond. Nat. Rev. Drug Discov. 11: 311-331
41. Clynes, R. 2007. Protective mechanisms of IVIG. Curr. Opin. Immunol. 19: 646-651
42. Sapir, T., and Y. Shoenfeld. 2005. Uncovering the hidden potential of intravenous immunoglobulin as an anticancer therapy. Clin. Rev. Allergy Immunol. 29: 307-310
43. Roca, H., Z. S. Varsos, S. Sud, M. J. Craig, C. Ying, and K. J. Pienta. 2009. CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-Type macrophage polarization. J. Biol. Chem. 284: 34342-34354
44. Kobayashi, M., M. G. Jeschke, K. Shigematsu, A. Asai, S. Yoshida, D. N. Herndon, and F. Suzuki. 2010. M2b monocytes predominated in peripheral blood of severely burned patients. J. Immunol. 185: 7174-7179
45. Matsushita, K., O. Takeuchi, D. M. Standley, Y. Kumagai, T. Kawagoe, T. Miyake, T. Satoh, H. Kato, T. Tsujimura, H. Nakamura, and S. Akira. 2009. Zc3h12a is an RNase essential for controlling immune responses by regulating mRNA decay. Nature 458: 1185-1190
46. Suzuki, H. I., M. Arase, H. Matsuyama, Y. L. Choi, T. Ueno, H. Mano, K. Sugimoto, and K. Miyazono. 2011. MCPIP1 ribonuclease antagonizes dicer and terminates microRNA biogenesis through precursor microRNA degradation. Mol. Cell 44: 424-436
47. Käsermann, F., D. J. Boerema, M. Rüegsegger, A. Hofmann, S. Wymann, A. W. Zuercher, and S. Miescher. 2012. Analysis and functional consequences of increased Fab-sialylation of intravenous immunoglobulin (IVIG) after lectin fractionation. PLoS One 7: e37243
48. Kajii, M., C. Suzuki, J. Kashihara, F. Kobayashi, Y. Kubo, H. Miyamoto, T. Yuuki, T. Yamamoto, and T. Nakae. 2011. Prevention of excessive collagen accumulation by human intravenous immunoglobulin treatment in a murine model of bleomycin-induced scleroderma. Clin. Exp. Immunol. 163: 235-241
49. Ballow, M. 2011. The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. J. Allergy Clin. Immunol. 127: 315-323, quiz 324-325.